The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. By drug class: Adalimumab segment is estimated to register highest CAGR of over 37.7%, thereby accounting for highest revenue share among the drug class segments. By application: Oncology segment is estimated to account for highest revenue share among the application segments, and register highest CAGR of over 38.0% over the forecast period. By region: Revenue from the market in Asia Pacific is expected to expand at a highest CAGR of over 36.9% over the forecast period.
2026 US$ 32,015.0 Mn: Global Biosimilar Monoclonal Antibodies Market is expected to reach US$ 32,015.0 Mn in 2026